Latigo Biotherapeutics, Inc. LTGO
IPO
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -21.04% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 10.12% | ||||
| Operating Income | -10.12% | ||||
| Income Before Tax | -12.35% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -12.35% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -12.35% | ||||
| EBIT | -10.12% | ||||
| EBITDA | -10.12% | ||||
| EPS Basic | -9.21% | ||||
| Normalized Basic EPS | -9.21% | ||||
| EPS Diluted | -9.21% | ||||
| Normalized Diluted EPS | -9.21% | ||||
| Average Basic Shares Outstanding | 2.87% | ||||
| Average Diluted Shares Outstanding | 2.87% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||